Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
126,786 studies indexed
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06663319 | A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers | recruiting | Phase 1 | 260 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06667076 | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(COPERNICUS) | recruiting | Phase 2 | 480 | Janssen Research & Development, LLC |
| 14 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT06667427 | Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06667908 | A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)(CONVERGE) | recruiting | Phase 2 | 130 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT06721065 | A Study of Language Interpretation Solutions for People With Breast Cancer | recruiting | N/A | 700 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06736717 | Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer(PANCONVA) | active not recruiting | Phase 1 / Phase 2 | 16 | University of Kansas Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06737913 | HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma(HAIBrave-001) | recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06744712 | Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients | not yet recruiting | N/A | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy(OrigAMI-3) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06754085 | Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | completed | Phase 3 | 131 | HTA Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | recruiting | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT06788964 | Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)(CORAL) | recruiting | Phase 2 | 29 | University of UtahOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06799351 | Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).(OzoParQTmicrob) | recruiting | Phase 2 / Phase 3 | 42 | Bernardino Clavo, MD, PhDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06800313 | Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 190 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06801236 | Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 88 | Acerand Therapeutics (Hong Kong) LimitedINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06816095 | Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment(OzoGynEpigen) | recruiting | — | 40 | Bernardino Clavo, MD, PhDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06817122 | The "Let's Talk Tech" Tool to Support Decision Making About Technology Use | completed | N/A | 222 | University of WashingtonOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06820268 | A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies | recruiting | Phase 1 | 168 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 25, 2026 | clinicaltrials |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)(cAMeLot-2) | recruiting | Phase 3 | 600 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT06855524 | Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer | recruiting | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer(ARTEMIDELung04) | recruiting | Phase 3 | 830 | AstraZenecaINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06877676 | Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Sep 25, 2026 | clinicaltrials |
| NCT06899308 | Health Surveillance at Constructor University Bremen (CUB)(CUB-HS2025) | active not recruiting | — | 373 | Jacobs University Bremen gGmbHOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06910670 | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid | active not recruiting | N/A | 197 | Washington University School of MedicineOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06919874 | Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery | recruiting | N/A | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy | terminated | Phase 2 | 18 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06929624 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma | active not recruiting | Phase 3 | 282 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06936527 | XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation(XS-03-II201) | enrolling by invitation | Phase 1 / Phase 2 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06952660 | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 4 | 100 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06963281 | Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | recruiting | Phase 1 | 285 | Fortvita Biologics (USA)Inc.INDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | recruiting | Phase 2 | 250 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07007559 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer(ASPEN-09-03) | recruiting | Phase 2 | 120 | ALX Oncology Inc.INDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07024680 | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC) | completed | — | 48 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)(DeLLphi-311) | recruiting | Phase 1 | 380 | AmgenINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | recruiting | Phase 2 | 120 | Hoffmann-La RocheINDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT07060014 | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | recruiting | Phase 1 | 22 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07066189 | Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC | recruiting | N/A | 160 | Yale UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07082920 | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | recruiting | Phase 1 | 140 | Janssen Research & Development, LLCINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07088991 | Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia(NEREUS) | recruiting | — | 200 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 3 days agoSource updated unknownsource: clinicaltrials